The company said Friday that it had submitted for approval of Yescarta in follicular and marginal zone lymphoma, based on data from the ZUMA-5 study that were presented at the 2020 ASCO meeting in May.
The company is seeking approval for Yescarta in follicular and marginal zone lymphomas. While it has a clear efficacy advantage over existing therapy options, experts said whether to use it in their place will entail complicated conversations with patients.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.